An activist tried to take on Pfizer. Then things got messy

• Pfizer CEO Albert Borla receives a strange email from the company's former CFO Frank D'Amelio, signaling the beginning of a chaotic activist investor campaign
• Pfizer's success with the Covid-19 vaccine leads to record highs in market cap, but challenges arise as the vaccine becomes old news and competitors emerge in the weight loss drug sector
• Pfizer's acquisition of cancer drug maker CGenta for $43 billion is criticized by investors, leading to a collapse in the company's share price and making it a prime target for an activist investor

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.